ALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance

Deep News10-20

ALEBUND-B (09637) shares briefly soared more than 47% in early trading. As of press time, the stock has pulled back to gain 11.04%, trading at HK$19.41, with a turnover of HK$81.8761 million.

Peking University First Hospital recently announced that the new drug clinical trial application for the next-generation AP308/PKU308, jointly developed by its Department of Nephrology and the company for the treatment of IgA nephropathy, has received approval from the U.S. FDA and is about to enter the first-in-human clinical research stage. On September 28, the application for AP308 for injection by Shanghai the company Technology Co., Ltd. was accepted by the Center for Drug Evaluation of the National Medical Products Administration. Shenwan Hongyuan previously released a research report stating that the company is an innovative drug enterprise focused on the CKD field, building a differentiated product matrix around disease-modifying therapy and complication management. It currently has one commercialized product and seven innovative candidate drugs, among which AP301, AP306, and AP303 have entered the critical development stage. The company integrates research, production, and commercialization, with all pipeline assets globally positioned, and is expected to achieve full value realization after listing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117823958?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-20 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117823958","market":"us","top_or_hot":-1,"title":"ALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance","media":"Deep News","content":"<p>ALEBUND-B (09637) shares briefly soared more than 47% in early trading. As of press time, the stock has pulled back to gain 11.04%, trading at HK$19.41, with a turnover of HK$81.8761 million.<br><br>Peking University First Hospital recently announced that the new drug clinical trial application for the next-generation AP308/PKU308, jointly developed by its Department of Nephrology and the company for the treatment of IgA nephropathy, has received approval from the U.S. FDA and is about to enter the first-in-human clinical research stage. On September 28, the application for AP308 for injection by Shanghai the company Technology Co., Ltd. was accepted by the Center for Drug Evaluation of the National Medical Products Administration. Shenwan Hongyuan previously released a research report stating that the company is an innovative drug enterprise focused on the CKD field, building a differentiated product matrix around disease-modifying therapy and complication management. It currently has one commercialized product and seven innovative candidate drugs, among which AP301, AP306, and AP303 have entered the critical development stage. The company integrates research, production, and commercialization, with all pipeline assets globally positioned, and is expected to achieve full value realization after listing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-10-20 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALEBUND-B (09637) shares briefly soared more than 47% in early trading. As of press time, the stock has pulled back to gain 11.04%, trading at HK$19.41, with a turnover of HK$81.8761 million.<br><br>Peking University First Hospital recently announced that the new drug clinical trial application for the next-generation AP308/PKU308, jointly developed by its Department of Nephrology and the company for the treatment of IgA nephropathy, has received approval from the U.S. FDA and is about to enter the first-in-human clinical research stage. On September 28, the application for AP308 for injection by Shanghai the company Technology Co., Ltd. was accepted by the Center for Drug Evaluation of the National Medical Products Administration. Shenwan Hongyuan previously released a research report stating that the company is an innovative drug enterprise focused on the CKD field, building a differentiated product matrix around disease-modifying therapy and complication management. It currently has one commercialized product and seven innovative candidate drugs, among which AP301, AP306, and AP303 have entered the critical development stage. The company integrates research, production, and commercialization, with all pipeline assets globally positioned, and is expected to achieve full value realization after listing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"","article_id":"1117823958","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117823958","pubTimestamp":1792463436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"ALEBUND-B (09637) shares briefly soared more than 47% in early trading. As of press time, the stock has pulled back to gain 11.04%, trading at HK$19.41, with a turnover of HK$81.8761 million.Peking...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1191":"制药","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","LABU":"三倍做多标普生物-Direxion","BK1574":"生物医药B类股","09637":"礼邦医药-B","09939":"开拓药业-B"},"translate_title":"随着 AP308 获得 FDA 临床批准和国内验收，ALEBUND-B 股价早盘飙升超过 47%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"LABU":1,"09637":1},"content_text":"ALEBUND-B (09637) shares briefly soared more than 47% in early trading. As of press time, the stock has pulled back to gain 11.04%, trading at HK$19.41, with a turnover of HK$81.8761 million.Peking University First Hospital recently announced that the new drug clinical trial application for the next-generation AP308/PKU308, jointly developed by its Department of Nephrology and the company for the treatment of IgA nephropathy, has received approval from the U.S. FDA and is about to enter the first-in-human clinical research stage. On September 28, the application for AP308 for injection by Shanghai the company Technology Co., Ltd. was accepted by the Center for Drug Evaluation of the National Medical Products Administration. Shenwan Hongyuan previously released a research report stating that the company is an innovative drug enterprise focused on the CKD field, building a differentiated product matrix around disease-modifying therapy and complication management. It currently has one commercialized product and seven innovative candidate drugs, among which AP301, AP306, and AP303 have entered the critical development stage. The company integrates research, production, and commercialization, with all pipeline assets globally positioned, and is expected to achieve full value realization after listing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117823958","isCrawlerRequest":true}